Table: Astellas -2025/26 group results (IFRS)

Astellas Pharma

27/04/2026 07:30

Apr 27 (Reuters)- 
              Astellas Pharma Inc. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   Year ended      Year ended       Year to        NEXT  
                Mar 31, 2026    Mar 31, 2025   Mar 31, 2027      YEAR    
                   LATEST         YEAR-AGO        COMPANY      COMPANY   
                   RESULTS         RESULT        FORECAST    H1 FORECAST 
  Sales           2.14 trln       1.91 trln      2.22 trln               
                 (+11.9 pct)     (+19.2 pct)    (+3.8 pct)               
  Operating        382.63           41.04         395.00                 
                (+832.4 pct)     (+60.8 pct)    (+3.2 pct)               
  Pretax           376.59           31.24         385.00                 
                                 (+25.1 pct)    (+2.2 pct)               
  Net              291.54           50.75         300.00                 
                (+474.5 pct)    (+197.7 pct)    (+2.9 pct)               
  EPS Basic      162.77 yen       28.35 yen     167.46 yen               
  EPS Diluted    162.22 yen       28.24 yen                              
  Ann Div         78.00 yen       74.00 yen      80.00 yen               
  -Q2 Div         39.00 yen       37.00 yen      40.00 yen               
  -Q4 Div         39.00 yen       37.00 yen      40.00 yen               
 
  NOTE - Astellas Pharma Inc.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T